Skip to main content
SpringerLink
Log in

Approaches to Hormonal Male Contraception

  • Chapter
  • First Online:
Andrology

  • 551 Accesses

Abstract

Currently, the most advanced approach to male contraception is a hormonal method. In principle, the suppression of spermatogenesis required for effective male contraception—while maintaining androgen-dependent functions—can be achieved with androgens alone, androgens in combination with GnRH antagonists, and androgens in combination with progestins. The closest to actual availability of such a method is the combined administration of testosterone and a progestin.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Al-Hendy A, Lukes AS, Poindexter AN 3rd, Venturella R, Villarroel C, Critchley HOD, Li Y, McKain L, Arjona Ferreira JC, Langenberg AGM, Wagman RB, Stewart EA (2021) Treatment of uterine fibroid symptoms with relugolix combination therapy. N Engl J Med 384:630–642

    CAS  PubMed  PubMed Central  Google Scholar 

  • Anawalt BD, Roth MY, Ceponis J, Surampudi V, Amory JK, Swerdloff RS, Liu PY, Dart C, Bremner WJ, Sitruk-Ware R, Kumar N, Blithe DL, Page ST, Wang C (2019) Combined nestorone-testosterone gel suppresses serum gonadotropins to concentrations associated with effective hormonal contraception in men. Andrology 7:878–887

    CAS  PubMed  PubMed Central  Google Scholar 

  • Attardi BJ, Hild SA, Reel JR (2006) Dimethandrolone undecanoate: a new potent orally active androgen with progestational activity. Endocrinology 147:3016–3026

    CAS  PubMed  Google Scholar 

  • Attardi BJ, Marck BT, Matsumoto AM, Koduri S, Hild SA (2011) Long-term effects of dimethandrolone 17beta-undecanoate and 11beta-methyl-19-nortestosterone 17beta-dodecylcarbonate on body composition, bone mineral density, serum gonadotropins, and androgenic/anabolic activity in castrated male rats. J Androl 32:183–192

    CAS  PubMed  Google Scholar 

  • Ayoub R, Page S, Swerdloff R, Liu P, Amory J, Leung A, Hull L, Blithe D, Christy A, Chao J, Bremner W, Wang C (2017) Comparison of the single dose pharmacokinetics, pharmacodynamics, and safety of two novel oral formulations of dimethandrolone undecanoate (DMAU): a potential oral, male contraceptive. Andrology 5:278–285

    CAS  PubMed  Google Scholar 

  • Barfield A, Melo J, Coutinho E, Alvarez-Sanchez F, Faundes A, Brache V, Leon P, Frick J, Bartsch G, Weiske WH, Brenner P, Mishell D Jr, Bernstein G, Ortiz A (1979) Pregnancies associated with sperm concentrations below 10 million/mL in clinical studies of a potential male contraceptive method, monthly depot medroxyprogesterone acetate and testosterone esters. Contraception 20:121–127

    CAS  PubMed  Google Scholar 

  • Bebb RA, Anawalt BD, Christensen RB, Paulsen CA, Bremner WJ, Matsumoto AM (1996) Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach. J Clin Endocrinol Metab 81:757–762

    CAS  PubMed  Google Scholar 

  • Behre HM, Nashan D, Hubert W, Nieschlag E (1992) Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception. J Clin Endocrinol Metab 74:84–90

    CAS  PubMed  Google Scholar 

  • Behre HM, Kliesch S, Keck C, Simoni M, Nieschlag E (1995) Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders. J Clin Endocrinol Metab 80:2394–2403

    CAS  PubMed  Google Scholar 

  • Behre HM, Kliesch S, Lemcke B, von Eckardstein S, Nieschlag E (2001) Suppression of spermatogenesis to azoospermia by combined administration of GnRH antagonist and 19-nortestosterone cannot be maintained by this non-aromatizable androgen alone. Hum Reprod 16:2570–2577

    CAS  PubMed  Google Scholar 

  • Behre HM, Wang C, Handelsman DJ, Nieschlag E (2004) Pharmacology of testosterone preparations. In: Nieschlag E, Behre HM (eds) Testosterone: action, deficiency, substitution, 3rd edn. Cambridge University Press, Cambridge, pp 405–444

    Google Scholar 

  • Behre HM, Zitzmann M, Anderson RA, Handelsman DJ, Lestari SW, McLachlan RI, Meriggiola MC, Misro MM, Noe G, Wu FC, Festin MP, Habib NA, Vogelsong KM, Callahan MM, Linton KA, Colvard DS (2016) Efficacy and safety of an injectable combination hormonal contraceptive for men. J Clin Endocrinol Metab 101:4779–4788

    CAS  PubMed  Google Scholar 

  • Blithe DL (2016) Pipeline for contraceptive development. Fertil Steril 106:1295–1302

    PubMed  PubMed Central  Google Scholar 

  • Brady BM, Walton M, Hollow N, Kicman AT, Baird DT, Anderson RA (2004) Depot testosterone with etonogestrel implants result in induction of azoospermia in all men for long-term contraception. Hum Reprod 19:2658–2667

    CAS  PubMed  Google Scholar 

  • von Eckardstein S, Noe G, Brache V, Nieschlag E, Croxatto H, Alvarez F, Moo-Young A, Sivin I, Kumar N, Small M, Sundaram K, International Committee for Contraception Research: The Population Council (2003) A clinical trial of 7 alpha-methyl-19-nortestosterone implants for possible use as a long-acting contraceptive for men. J Clin Endocrinol Metab 88:5232–5239

    Google Scholar 

  • Grimes DA, Lopez LM, Gallo MF, Halpern V, Nanda K, Schulz KF (2012) Steroid hormones for contraception in men. Cochrane Database Syst Rev 3:CD004316

    Google Scholar 

  • Gu Y, Wang X, Xu D, Peng L, Cheng L, Huang M, Huang Z, Zhang G (2003) A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men. J Clin Endocrinol Metab 88:562–568

    CAS  PubMed  Google Scholar 

  • Gu Y, Liang X, Wu W, Liu M, Song S, Cheng L, Bo L, Xiong C, Wang X, Liu X, Peng L, Yao K (2009) Multicenter contraceptive efficacy trial of injectable testosterone undecanoate in Chinese men. J Clin Endocrinol Metab 94:1910–1915

    CAS  PubMed  Google Scholar 

  • Heckel M (1939) Production of oligospermia in a man by the use of testosterone propionate. Proc Soc Exp Biol Med 40:658–659

    Google Scholar 

  • Heinemann K, Saad F, Wiesemes M, White S, Heinemann L (2005) Attitudes toward male fertility control: results of a multinational survey on four continents. Hum Reprod 20:549–556

    PubMed  Google Scholar 

  • Ilani N, Roth MY, Amory JK, Swerdloff RS, Dart C, Page ST, Bremner WJ, Sitruk-Ware R, Kumar N, Blithe DL, Wang C (2012) A new combination of testosterone and nestorone transdermal gels for male hormonal contraception. J Clin Endocrinol Metab 97:3476–3486

    CAS  PubMed  PubMed Central  Google Scholar 

  • Kamischke A, Plöger D, Venherm S, von Eckardstein S, von Eckardstein A, Nieschlag E (2000) Intramuscular testosterone undecanoate with or without oral levonorgestrel: a randomized placebo-controlled feasibility study for male contraception. Clin Endocrinol 53:43–52

    CAS  Google Scholar 

  • Kamischke A, Venherm S, Plöger D, von Eckardstein S, Nieschlag E (2001) Intramuscular testosterone undecanoate and norethisterone enanthate in a clinical trial for male contraception. J Clin Endocrinol Metab 86:303–309

    CAS  PubMed  Google Scholar 

  • Kamischke A, Heuermann T, Krüger K, von Eckardstein S, Schellschmidt I, Rübig A, Nieschlag E (2002) An effective hormonal male contraceptive using testosterone undecanoate with oral or injectable norethisterone preparations. J Clin Endocrinol Metab 87:530–539

    CAS  PubMed  Google Scholar 

  • Kinniburgh D, Anderson RA, Baird DT (2001) Suppression of spermatogenesis with desogestrel and testosterone pellets is not enhanced by addition of finasteride. J Androl 22:88–95

    CAS  PubMed  Google Scholar 

  • Knuth UA, Behre HM, Belkien L, Bents H, Nieschlag E (1985) Clinical trial of 19-nortestosterone-hexoxyphenylpropionate (Anadur) for male fertility regulation. Fertil Steril 44:814–821

    CAS  PubMed  Google Scholar 

  • Knuth UA, Yeung CH, Nieschlag E (1989) Combination of 19-nortestosterone-hexyloxyphenylpropionate (Anadur) and depot-medroxyprogesterone-acetate (Clinovir) for male contraception. Fertil Steril 51:1011–1018

    CAS  PubMed  Google Scholar 

  • Liu PY, Swerdloff RS, Christenson PD, Handelsman DJ, Wang C, Hormonal Male Contraception Summit Group (2006) Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis. Lancet 367:1412–1420

    CAS  PubMed  Google Scholar 

  • Liu PY, Swerdloff RS, Anawalt BD, Anderson RA, Bremner WJ, Elliesen J, Gu YQ, Kersemaekers WM, McLachlan RI, Meriggiola MC, Nieschlag E, Sitruk-Ware R, Vogelsong K, Wang XH, Wu FC, Zitzmann M, Handelsman DJ, Wang C (2008) Determinants of the rate and extent of spermatogenic suppression during hormonal male contraception: an integrated analysis. J Clin Endocrinol Metab 93:1774–1783

    CAS  PubMed  PubMed Central  Google Scholar 

  • Long JE, Lee MS, Blithe DL (2019) Male contraceptive development: update on novel hormonal and nonhormonal methods. Clin Chem 65:153–160

    CAS  PubMed  Google Scholar 

  • Mahabadi V, Amory JK, Swerdloff RS, Bremner WJ, Page ST, Sitruk-Ware R, Christensen PD, Kumar N, Tsong YY, Blithe D, Wang C (2009) Combined transdermal testosterone gel and the progestin nestorone suppresses serum gonadotropins in men. J Clin Endocrinol Metab 94:2313–2320

    CAS  PubMed  PubMed Central  Google Scholar 

  • McLachlan RI, McDonald J, Rushford D, Robertson DM, Garrett C, Baker HW (2000) Efficacy and acceptability of testosterone implants, alone or in combination with a 5alpha-reductase inhibitor, for male hormonal contraception. Contraception 62:73–78

    CAS  PubMed  Google Scholar 

  • Meriggiola MC, Costantino A, Cerpolini S, Bremner WJ, Huebler D, Morselli-Labate AM, Kirsch B, Bertaccini A, Pelusi C, Pelusi G (2003) Testosterone undecanoate maintains spermatogenic suppression induced by cyproterone acetate plus testosterone undecanoate in normal men. J Clin Endocrinol Metab 88:5818–5826

    CAS  PubMed  Google Scholar 

  • Meriggiola MC, Costantino SF, D’Emidio L, Morselli Labate AM, Bertaccini A, Bremner WJ, Rudolph I, Ernst M, Kirsch B, Martorana G, Pelusi G (2005) Norethisterone enanthate plus testosterone undecanoate for male contraception: effects of various injection intervals on spermatogenesis, reproductive hormones, testis, and prostate. J Clin Endocrinol Metab 90:2005–2014

    CAS  PubMed  Google Scholar 

  • Mommers E, Kersemaeker WM, Elliesen J, Kepers M, Apter D, Behre HM, Beynon J, Bouloux PM, Costantino A, Gerbershagen HP, Gronlund L, Heger-Mahn D, Huhtaniemi I, Koldewihn EL, Lange C, Lindenberg S, Meriggiola MC, Meuleman E, Mulder PFA, Nieschlag E, Perheentupa A, Solomon A, Väisälä L, Wu FC, Zitzmann M (2008) Male hormonal contraception: a double-blind, placebo-controlled study. J Clin Endocrinol Metab 93:2572–2580

    CAS  PubMed  Google Scholar 

  • Nguyen BT, Farrant MT, Anawalt BD, Yuen F, Thirumalai A, Amory JK, Swerdloff RS, Bremner WJ, Liu PY, Blithe DL, Page ST, Wang C (2020) Acceptability of oral dimethandrolone undecanoate in a 28-day placebo-controlled trial of a hormonal male contraceptive prototype. Contraception 102:52–57

    CAS  PubMed  PubMed Central  Google Scholar 

  • Nieschlag E (2007) 10th summit meeting consensus: recommendations for regulatory approval for hormonal male contraception. October 22–23, 2006. Contraception 75:166–167

    Google Scholar 

  • Nieschlag E, Hoogen H, Bölk M, Schuster H, Wickings EJ (1978) Clinical trial with testosterone undecanoate for male fertility control. Contraception 18:607–614

    CAS  PubMed  Google Scholar 

  • Nieschlag E, Kamischke A, Behre HM (2004) Hormonal male contraception: the essential role of testosterone. In: Nieschlag E, Behre HM (eds) Testosterone: action, deficiency, substitution, 3rd edn. Cambridge University Press, Cambridge, pp 685–714

    Google Scholar 

  • Nieschlag E, Kumar N, Sitruk-Ware R (2013) 7α-methyl-19-nortestosterone (MENT): the population council’s contribution to research on male contraception and treatment of hypogonadism. Contraception 87:288–295

    CAS  PubMed  Google Scholar 

  • Page ST, Amory JK, Anawalt BD, Irwig MS, Brockenbrough AT, Matsumoto AM, Bremner WJ (2006) Testosterone gel combined with depomedroxyprogesterone acetate is an effective male hormonal contraceptive regimen and is not enhanced by the addition of a GnRH antagonist. J Clin Endocrinol Metab 91:4374–4380

    CAS  PubMed  Google Scholar 

  • Qoubaitary A, Meriggiola C, Ng CM, Lumbreras L, Cerpolini S, Pelusi G, Christensen PD, Hull L, Swerdloff RS, Wang C (2006) Pharmacokinetics of testosterone undecanoate injected alone or in combination with norethisterone enanthate in healthy men. J Androl 27:853–867

    CAS  PubMed  Google Scholar 

  • Roth MY, Shih G, Ilani N, Wang C, Page ST, Bremner WJ, Swerdloff RS, Sitruk-Ware R, Blithe DL, Amory JK (2014) Acceptability of a transdermal gel-based male hormonal contraceptive in a randomized controlled trial. Contraception 90:407–412

    CAS  PubMed  PubMed Central  Google Scholar 

  • Schlaff WD, Ackerman RT, Al-Hendy A, Archer DF, Barnhart KT, Bradley LD, Carr BR, Feinberg EC, Hurtado SM, Kim J, Liu R, Mabey RG Jr, Owens CD, Poindexter A, Puscheck EE, Rodriguez-Ginorio H, Simon JA, Soliman AM, Stewart EA, Watts NB, Muneyyirci-Delale O (2020) Elagolix for heavy menstrual bleeding in women with uterine fibroids. N Engl J Med 382:328–340

    CAS  PubMed  Google Scholar 

  • Serfaty D, Sitruk-Ware R, Nieschlag E, Anderson RA, Behre HM, Bouchard P, Bremner WJ, Danielsson KG, Matzuk MM, Meriggiola MC, Page ST, Simmons NL, Sokal DC, Swerdloff R, Townsend J, Wang C, Wu F (2016) Das Pariser Manifest: Es ist Zeit für neue männliche Kontrazeptiva. J Reproduktionsmed Endokrinol 13:78–79

    Google Scholar 

  • Serfaty D, Sitruk-Ware R, Nieschlag E, Anderson RA, Behre HM, Bouchard P, Bremner WJ, Danielsson KG, Matzuk MM, Meriggiola MC, Page ST, Simmons NL, Sokal DC, Swerdloff R, Townsend J, Wang C, Wu F (2018) Das Zweite Pariser Manifest vom 7. Mai 2018: Männliche Kontrazeption auf dem Vormarsch. J Reproduktionsmed Endokrinol 15:171–172

    Google Scholar 

  • Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, Akaza H, Bossi A, van Veenhuyzen DF, Selby B, Fan X, Kang V, Walling J, Tombal B, HERO Study Investigators (2020) Oral Relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med 382:2187–2196

    CAS  PubMed  Google Scholar 

  • Soufir JC, Meduri G, Ziyyat A (2011) Spermatogenetic inhibition in men taking a combination of oral medroxyprogesterone acetate and percutaneous testosterone as a male contraceptive method. Hum Reprod 26:1708–1714

    CAS  PubMed  Google Scholar 

  • Swerdloff RS, Bagatell CJ, Wang C, Anawalt BD, Berman N, Steiner B, Bremner WJ (1998) Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone. J Clin Endocrinol Metab 83:3527–3533

    CAS  PubMed  Google Scholar 

  • Thirumalai A, Ceponis J, Amory JK, Swerdloff R, Surampudi V, Liu PY, Bremner WJ, Harvey E, Blithe DL, Lee MS, Hull L, Wang C, Page ST (2018) Effects of 28 days of oral dimethandrolone undecanoate in healthy men: a prototype male pill. J Clin Endocrinol Metab 104:423–432

    PubMed Central  Google Scholar 

  • Thirumalai A, Yuen F, Amory JK, Hoofnagle AN, Swerdloff RS, Liu PY, Long JE, Blithe DL, Wang C, Page ST (2021) Dimethandrolone undecanoate, a novel, nonaromatizable androgen, increases P1NP in healthy men over 28 days. J Clin Endocrinol Metab 106:e171–e181

    PubMed  Google Scholar 

  • Turner L, Conway AJ, Jimenez M, Liu PY, Forbes E, McLachlan RI, Handelsman DJ (2003) Contraceptive efficacy of a depot progestin and androgen combination in men. J Clin Endocrinol Metab 88:4659–4667

    CAS  PubMed  Google Scholar 

  • Waites GMH (2003) Development of methods of male contraception: impact of the World Health Organization task force. Fertil Steril 80:1–15

    PubMed  Google Scholar 

  • Walton MJ, Kumar N, Baird DT, Ludlow H, Anderson RA (2007) 7α-Methyl-19-nortestosterone (MENT) vs. testosterone in combination with etonogestrel implants for spermatogenic suppression in healthy men. J Androl 28:679–688

    CAS  PubMed  Google Scholar 

  • Wang C, Wang XH, Nelson AL (2005) Levonorgestrel implants enhanced the suppression of spermatogenesis by testosterone implants: comparison between Chinese and non-Chinese men. J Clin Endocrinol Metab 91:460–470

    PubMed  Google Scholar 

  • Wang C, Cui YG, Wang XH, Jia Y, Hikim AS, Lue YH, Tong JS, Qian LX, Sha JH, Zhou ZM, Hull L, Leung A, Swerdloff RS (2007) Transient scrotal hyperthermia and levonorgestrel enhance testosterone-induce spermatogenesis suppression in men through increased germ cell apoptosis. J Clin Endocrinol Metab 92:3292–3304

    CAS  PubMed  Google Scholar 

  • WHO Task Force on Methods for the Regulation of Male Fertility (1990) Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet 336:955–959

    Google Scholar 

  • WHO Task Force on Methods for the Regulation of Male Fertility (1993) Comparison of two androgens plus depot-medroxyprogesterone acetate for suppression to azoospermia in Indonesian men. Fertil Steril 60:1062

    Google Scholar 

  • WHO Task Force on Methods for the Regulation of Male Fertility (1996) Contraceptive efficacy of testosterone-induce azoospermia and oligozoospermia in normal men. Fertil Steril 65:821–829

    Google Scholar 

  • Wistuba J, Nieschlag E, Semjonow A, Sandhowe-Klaverkamp R, Friderichs-Gromoll S, Zitzmann M, Simoni M, Luetjens CM (2012) Testosterone-induced prostate growth is blocked by co- and preadministration of norethisterone enanthate in castrated cynomolgus monkeys. Urol Int 88:358–364

    CAS  PubMed  Google Scholar 

  • Wu FC, Balasubramanian R, Mulders TM, Coeling-Benning HJ (1999) Oral progestogen combined with testosterone as a potential male contraceptive: additive effects between desogestrel and testosterone enanthate in suppression of spermatogenesis, pituitary-testicular axis, and lipid metabolism. J Clin Endocrinol Metab 84:112–122

    CAS  PubMed  Google Scholar 

  • Wu S, Yuen F, Swerdloff RS, Pak Y, Thirumalai A, Liu PY, Amory JK, Bai F, Hull L, Blithe DL, Anawalt BD, Parman T, Kim K, Lee MS, Bremner WJ, Page ST, Wang C (2019) Safety and pharmacokinetics of single-dose novel oral androgen 11β-methyl-19-nortestosterone-17β-dodecylcarbonate in men. J Clin Endocrinol Metab 104:629–638

    PubMed  Google Scholar 

  • Yuen F, Wu S, Thirumalai A, Swerdloff RS, Page ST, Liu PY, Dart C, Wu H, Blithe DL, Sitruk-Ware R, Long J, Bai F, Hull L, Bremner WJ, Anawalt BD, Wang C (2019) Preventing secondary exposure to women from men applying a novel nestorone/testosterone contraceptive gel. Andrology 7:235–243

    CAS  PubMed  Google Scholar 

  • Yuen F, Thirumalai A, Pham C, Swerdloff RS, Anawalt BD, Liu PY, Amory JK, Bremner WJ, Dart C, Wu H, Hull L, Blithe DL, Long J, Wang C, Page ST (2020) Daily oral administration of the novel androgen 11β-MNTDC markedly suppresses serum gonadotropins in healthy men. J Clin Endocrinol Metab 105:e835–e847

    PubMed  PubMed Central  Google Scholar 

  • Zhang GY, Gu YQ, Wang XH, Cui YG, Bremner WJ (1999) A clinical trial of injectable testosterone undecanoate as a potential male contraceptive in normal Chinese men. J Clin Endocrinol Metab 84:3642–3647

    CAS  PubMed  Google Scholar 

  • Zitzmann M, Rohayem J, Raidt J, Kliesch S, Kumar N, Sitruk-Ware R, Nieschlag E (2017) Impact of various progestins with or without transdermal testosterone on gonadotropin levels for non-invasive hormonal male contraception: a randomized clinical trial. Andrology 5:516–526

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Reproductive Medicine and Andrology, University Hospital Halle (Saale), Halle (Saale), Germany

    Hermann M. Behre

  2. Contraceptive Development Program, DIPHR, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA

    Diana L. Blithe

  3. Center of Reproductive Medicine and Andrology, University Hospital Münster, Münster, Germany

    Eberhard Nieschlag

Authors
  1. Hermann M. Behre
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Diana L. Blithe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eberhard Nieschlag
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hermann M. Behre .

Editor information

Editors and Affiliations

  1. Center for Reproductive Medicine and Andrology, University Hospital Münster, Münster, Germany

    Eberhard Nieschlag

  2. Center for Reproductive Medicine and Andrology, University Hospital Halle (Saale), Martin Luther University Halle-Wittenberg, Halle (Saale), Germany

    Hermann M. Behre

  3. Center for Reproductive Medicine and Andrology, University Hospital Münster, Münster, Germany

    Sabine Kliesch

  4. Center for Reproductive Medicine and Andrology, University Hospital Münster, Münster, Germany

    Susan Nieschlag

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Behre, H.M., Blithe, D.L., Nieschlag, E. (2023). Approaches to Hormonal Male Contraception. In: Nieschlag, E., Behre, H.M., Kliesch, S., Nieschlag, S. (eds) Andrology. Springer, Cham. https://doi.org/10.1007/978-3-031-31574-9_47

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-31574-9_47

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-31573-2

  • Online ISBN: 978-3-031-31574-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation